Strategy+ advised one of the world’s premier biopharmaceutical companies Pfizer (NYSE: PFE) on the acquisition of Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC). The definitive merger agreement was announced May 16, 2016. Pfizer agreed to acquire Anacor for a total transaction value of $5.2 Billion in cash.